Acacia Pharma logo

ACPH - Acacia Pharma Share Price

€2.74 -0.0  -1.1%

Last Trade - 4:35pm

Sector
Healthcare
Size
Small Cap
Market Cap £239.5m
Enterprise Value £227.7m
Revenue £n/a
Position in Universe 411th / 846
Bullish
Bearish
Unlock ACPH Revenue
Momentum
Relative Strength (%)
1m -15.7%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -21.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 0.100 7.08
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Acacia PharmaGroup PLC revenues was not reported. Net loss increased 16%to $15.2M. Higher net loss reflects Administrative Expensesincrease of 96% to $4.4M (expense), Foreign ExchangeGain/LossNon-Business increase from $153K to $1.1M(expense), Other Non-Operating Income/Expense increase from$721K to $1.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ACPH
Graphical History

Revenue

ACPH Revenue Unlock ACPH Revenue

Net Income

ACPH Net Income Unlock ACPH Revenue

Normalised EPS

ACPH Normalised EPS Unlock ACPH Revenue

PE Ratio Range

ACPH PE Ratio Range Unlock ACPH Revenue

Dividend Yield Range

ACPH Dividend Yield Range Unlock ACPH Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ACPH EPS Forecasts Unlock ACPH Revenue
Profile Summary

Acacia Pharma Group PLC is a United Kingdom-based company specialized in the pharmaceutical industry. The pharmaceutical group focuses on the development and commercialization of new nausea and vomiting treatments for surgical and cancer patients. Its pipeline includes BAREMIS, an intravenous formulation of amisulpride, which is a selective dopamine antagonist that has completed phase 3 clinical development for the prophylaxis and treatment of Postoperative nausea and vomiting (PONV), and APD403, which is based on the selective dopamine antagonist amisulpride and it is being developed as an intravenous injection for cancer patients to be administered immediately before chemotherapy to prevent acute chemotherapy-induced nausea & vomiting ( CINV).

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated September 2, 2015
Public Since March 5, 2018
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Euronext - Brussels
Shares in Issue 99,689,451
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ACPH Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ACPH
Upcoming Events for ACPH
Frequently Asked Questions for Acacia Pharma
What is the Acacia Pharma share price?

As of 4:35pm, shares in Acacia Pharma are trading at €2.74, giving the company a market capitalisation of £239.5m. This share price information is delayed by 15 minutes.

How has the Acacia Pharma share price performed this year?

Shares in Acacia Pharma are currently trading at €2.74 and the price has moved by -0.9% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Acacia Pharma price has moved by -5.28% over the past year.

What are the analyst and broker recommendations for Acacia Pharma?

Of the analysts with advisory recommendations for Acacia Pharma, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Acacia Pharma is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Acacia Pharma next release its financial results?

Acacia Pharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Acacia Pharma dividend yield?

Acacia Pharma does not currently pay a dividend.

Does Acacia Pharma pay a dividend?

Acacia Pharma does not currently pay a dividend.

When does Acacia Pharma next pay dividends?

Acacia Pharma does not currently pay a dividend.

How do I buy Acacia Pharma shares?

To buy shares in Acacia Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Acacia Pharma?

Shares in Acacia Pharma are currently trading at €2.74, giving the company a market capitalisation of £239.5m.

Where are Acacia Pharma shares listed? Where are Acacia Pharma shares listed?

Here are the trading details for Acacia Pharma:

Country of listing: Belgium
Exchange: BRU
Ticker Symbol: ACPH
What kind of share is Acacia Pharma?

Based on an overall assessment of its quality, value and momentum, Acacia Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Acacia Pharma share price forecast 2021?

Shares in Acacia Pharma are currently priced at €2.74. At that level they are trading at 0.302% discount to the analyst consensus target price of 0.00.

Analysts covering Acacia Pharma currently have a consensus Earnings Per Share (EPS) forecast of -0.398641824 for the next financial year.

How can I tell whether the Acacia Pharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acacia Pharma. Over the past six months, the relative strength of its shares against the market has been 10.2%. At the current price of €2.74, shares in Acacia Pharma are trading at 7.18% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Acacia Pharma PE Ratio?

We were not able to find PE ratio data for Acacia Pharma.

Who are the key directors of Acacia Pharma?

Acacia Pharma's management team is headed by:

Scott Byrd - NED
John Brown - NID
Edward Borkowski - NID
Gabriel Fox - OTH
Michael Bolinder - CEO
Gary Gemignani - CFO
Anne-Marie Elsley - SEC
Who are the major shareholders of Acacia Pharma?

Here are the top five shareholders of Acacia Pharma based on the size of their shareholding:

Cosmo Technologies, Ltd. Corporation
Percentage owned: 19.66% (19.6m shares)
Gilde Equity Management Benelux B.V. Private Equity
Percentage owned: 17% (16.9m shares)
Lundbeckfond Invest Investment Advisor
Percentage owned: 12.51% (12.5m shares)
Fidelity International Investment Advisor
Percentage owned: 5.01% (5.00m shares)
AXA Investment Managers UK Ltd. Investment Advisor/Hedge Fund
Percentage owned: 2.66% (2.65m shares)
Similar to ACPH
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.